The diabetes treatment market is expected to remain active in October. This is because salt-modifying complex drugs that were not registered in September are hitting the market all at once. According to the industry on the 20th, generics of MSD's DPP-4 inhibitory diabetes combination drug 'Janumet and Janumet XR' will be listed in large numbers next month.

These are salt-modifying drugs, and due to the calculation criteria, they were not released when the patent expired on September 2nd. This is because salt-modified complex drugs can only be calculated if a single salt-modified drug with the same ingredient is registered first. Sitagliptin hydrochloride hydrate complex drugs are scheduled to be regist